Welcome to our dedicated page for Savara news (Ticker: SVRA), a resource for investors and traders seeking the latest updates and insights on Savara stock.
Savara Inc. (symbol: SVRA) is a specialty biopharmaceutical company that focuses on developing innovative therapies for rare respiratory diseases. The company’s principal approach centers on addressing serious and life-threatening pulmonary conditions. Its flagship product, AeroVanc, is the first-ever dry powder inhaled antibiotic specifically designed to treat methicillin-resistant Staphylococcus aureus (MRSA) infections in patients with cystic fibrosis (CF). This groundbreaking treatment aims to improve the quality of life and health outcomes for these patients.
Another significant project by Savara is the molgramostim nebulizer solution (molgramostim). This is an inhaled granulocyte-macrophage colony-stimulating factor currently in Phase 3 development for treating autoimmune pulmonary alveolar proteinosis (aPAP). aPAP is a rare and often debilitating lung disease with limited treatment options, and molgramostim seeks to fill this critical gap.
Savara's dedication to addressing unmet medical needs is evident through its focused development pipeline. The company operates as a single-segment entity specializing in respiratory system pharmaceuticals, highlighting its concentrated expertise and commitment to improving respiratory health.
In terms of financial health and partnerships, Savara has made strategic moves to secure funding and collaborations that bolster its research and development efforts. These partnerships and financial strategies are crucial for advancing its clinical programs and bringing innovative treatments to market.
For more detailed information on the company and its projects, please visit Savara’s official websites at www.savarapharma.com and www.aerovanc.com.
Savara Inc. (NASDAQ: SVRA) announced on April 22, 2022, the grant of inducement awards to two new employees, comprising options to purchase 55,000 shares of common stock. The options have an exercise price of $1.23 per share, the closing price on the grant date. Each option features a 10-year term and vests quarterly based on the employee's continued service. Savara focuses on rare respiratory diseases, with its lead program, molgramostim nebulizer solution, in Phase 3 development for autoimmune pulmonary alveolar proteinosis.
Savara Inc. (NASDAQ: SVRA) has secured a $26.5 million term loan from Silicon Valley Bank to refinance its existing credit facility. The new loan features a lower interest rate of prime minus 0.50% and an initial 48-month interest-only period, enhancing the company's financial flexibility. With a cash position of approximately $161 million as of 2021, Savara believes it is funded through 2025, coinciding with the anticipated data read-out from its Phase 3 clinical trial of molgramostim.
Savara Inc. (Nasdaq: SVRA) provided a business update and reported its financial results for Q4 and FY 2021. The company is advancing its Phase 3 IMPALA-2 trial for molgramostim, activating most of the ~50 clinical sites, and anticipates top-line data by the end of Q2 2024. Financially, Savara ended 2021 with approximately $161M in cash and reduced its net loss to $11.3M in Q4 2021, compared to $13.7M in Q4 2020. For the entire year, the net loss decreased to $43M from $49.6M, attributed mainly to reduced R&D costs and improved financial discipline.
Savara Inc. (NASDAQ: SVRA), a biopharmaceutical company focused on rare respiratory diseases, announced the granting of an employee inducement award on March 14, 2022. The award includes options to purchase 40,000 shares of common stock at an exercise price of $1.05 per share, matching the closing price on the grant date. The options vest quarterly over a 10-year term, contingent on the employee's continued employment. Savara's lead program, molgramostim, is currently in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Savara Inc. (NASDAQ: SVRA), a clinical stage biopharmaceutical company, announced its participation in Oppenheimer’s 32nd Annual Healthcare Conference on March 16, 2022, at 3:20 pm ET. The presentation will focus on their lead program, molgramostim, an inhaled treatment for autoimmune pulmonary alveolar proteinosis (aPAP), currently in Phase 3 development. A live webcast will be available on Savara’s website and archived for 90 days. Savara is dedicated to advancing therapies for rare respiratory diseases.
Savara Inc. (NASDAQ: SVRA), a clinical-stage biopharmaceutical company, announced its participation in the H.C. Wainwright BIOCONNECT Virtual Conference from January 10-13, 2022. The management team will present on January 10, 2022, at 7:00 AM ET. A webcast of the presentation will be accessible on Savara’s website and archived for 90 days. The company focuses on rare respiratory diseases, with its lead program, molgramostim nebulizer solution, in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Savara Inc. (NASDAQ: SVRA), a clinical stage biopharmaceutical company, announced the grant of inducement awards to five new employees on December 1, 2021. The awards consist of options to purchase a total of 280,000 shares of common stock at an exercise price of $1.08 per share, matching the closing price on the grant date. These options have a 10-year term and vest quarterly. Savara focuses on rare respiratory diseases, with its lead program being molgramostim nebulizer solution in Phase 3 for autoimmune pulmonary alveolar proteinosis (aPAP).
Savara Inc. (NASDAQ: SVRA), a biopharmaceutical company specializing in rare respiratory diseases, announced its participation in two upcoming healthcare conferences. The company will present a pre-recorded webcast at the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22, 2021, at 10:00 AM ET. Additionally, a live webcast of a fireside chat will occur during the Evercore ISI 4th Annual HealthCONx Virtual Conference on November 30, 2021, at 8:50 AM ET. The webcasts will be accessible on Savara's investor page for 90 days.
Savara Inc. (SVRA) advanced its Phase 3 IMPALA 2 trial for Molgramostim in autoimmune pulmonary alveolar proteinosis, with a 20-month enrollment timeline on track. The European Medicines Agency accepted its revised Pediatric Investigation Plan. The company ended Q3 2021 with approximately $171 million in cash, sufficient to cover operations through 2025, beyond the anticipated IMPALA-2 data readout in late Q2 2024. Financial results showed a net loss of $10.5 million, a decrease from $11.1 million in Q3 2020, and a 16.6% rise in R&D expenses due to trial progression.
Savara Inc. (NASDAQ: SVRA), a clinical stage biopharmaceutical company focusing on rare respiratory diseases, will present at the Jefferies London Healthcare Conference from November 16-19, 2021. A pre-recorded, on-demand webcast of the presentation will be available starting November 18 at 3:00 am ET until November 19 at 12:00 pm ET. The replay will be accessible on Savara's Investors page for 90 days post-event. Savara's lead product, molgramostim, is in Phase 3 development for autoimmune pulmonary alveolar proteinosis.
FAQ
What is the current stock price of Savara (SVRA)?
What is the market cap of Savara (SVRA)?
What does Savara Inc. specialize in?
What is AeroVanc?
What is molgramostim?
What is autoimmune pulmonary alveolar proteinosis (aPAP)?
Where can I find more information about Savara Inc.?
How is Savara Inc. funded?
What is the main focus of Savara's development pipeline?
Is AeroVanc currently available on the market?
What stage is molgramostim in?
Does Savara Inc. have any other products in development?
